Aalberts: highlights ING Benelux Conference Brussels 2024, Ackermans & Van Haaren: Highlights ING Benelux Conference Brussels,Ackermans & Van Haaren: Strong operational performance of underlying companies and guidance fine-tuned upwards, AMG: Highlights ING Benelux Conference Brussels, Aperam: Highlights ING Benelux Conference Brussels, Arcadis: Highlights ING Benelux conference, Azelis: Highlights ING Benelux Conference Brussels, Bekaert: Guidance cut and €200m buyback as sweetener, CFE: No new...
UCB has received a 5th nod for Bimzelx as hidradenitis suppurativa joins the fray of approved indications. We see an important role for Bimzelx in this emerging disease space with clear potential to become standard of care over time given its clear outperformance over Novartis' Cosentyx in the clinic. We reiterate our € 173 TP and Accumulate rating.
UCB shared first insights into the Phase 3 data on dapimap in SLE, which appear generally favourable with a 14.6% BICLA benefit after 48 weeks vs. SoC. The data also shows a steroid tapering effect and reduction in flares, while suggesting possible outperformance vs. current market leader Benlysta (GSK). Dapimap is co-developed with Biogen and will be continued in a second Ph3 study. We reiterate our € 173 TP and Accumulate rating.
While 1H results were overall good with guidance being reconfirmed, RET showed some level of cautiousness on tenants and consumers' environment. Certain tenants' profitability appears to be under pressure, while consumers have a more cautious approach to spending. On a positive note, out of 22 stores left empty from problematic tenants (out of a total of >1000 store), 11 already have a new occupier. For contracts that are to be renegotiated over the next 6 to 12 months, there are no discussions ...
RET reported its 1H24/25 results (September end) slightly below our estimates. EPRA Net profit grew 1.9%. EPRA EPS amounted to EUR 3.12 vs. our expectation of 3.16. NRI grew 4.6% to 70.6m vs. 72.2.9m expected. Occupancy declined slightly to 97.6% from 97.9%. Retail Estates was confronted with some bankruptcies in the toy (Fun) and fashion (Euro Shoe) segment, but has so far managed the re-letting extremely well. These bankruptcies have soured the sentiment on the stock. However, RET confirmed i...
Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program Amsterdam, November 18, 2024 – Arcadis (EURONEXT: ARCAD), the leading data driven global Design & Consultancy organization for natural and built assets, has repurchased 67,797 of its own shares in the period 11 November – 15 November 2024 at an average price of €64.39. The total consideration of this repurchase was €4,365,632. The repurchase is in accordance with the share buyback program to cover existing and expected future obligations under Arcadis...
We reiterate our BUY rating on UCB and increase our target price from €180 to €212. After almost a year on the ING Benelux Favourites List, we believe it is an opportune time to remove UCB as we view our upside as more risky than in the past as it is increasingly weighted towards UCB's development pipeline. Nonetheless, we remain confident in UCB's equity story, driven by INGF €6bn peak sales for Bimzelx, a continued strong performance of secondary growth engines Evenity and Rystiggo, as well as...
Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program Amsterdam, November 11, 2024 – Arcadis (EURONEXT: ARCAD), the leading data driven global Design & Consultancy organization for natural and built assets, has repurchased 39,537 of its own shares in the period 4 November – 8 November 2024 at an average price of €65.18. The total consideration of this repurchase was €2,576,847. The repurchase is in accordance with the share buyback program to cover existing and expected future obligations under Arcadis’ ...
CMB.TECH’s diversified and ‘future-proof’ approach may prove attractive in steadily managing shipping cycles, changing fundamentals and stricter environmental regulations. However, diversification also comes at a price, and its heavy newbuild programme is straining its balance sheet and the outlook for dividends. Thus, we currently see greater upside potential in its pure crude tanker peers. We reiterate our HOLD and have lowered our target price to USD14.1 (16.3).
Aalberts: Building already bottoming, industry tough. Air France-KLM: Nobody helps. Alfen: Covenant agreement, hikes output Smart Grid. AMG: Sweet for 2024F, sour for 2025F. ArcelorMittal: 3Q24 EBITDA beats by 6%, FCF solid. BAM: 3Q beats, on its way to reach FY guidance. CMB.TECH: 3Q and FY24 reasonable but then more challenges. D'Ieteren: EGM and dividend dates announced; Belron US peer Boyd disappointing 3Q24. GBL: Double-digit TSR expected over 2024-27F. KBC: 3Q better acro...
Adecco: 3Q24 miss; stabilising trends in 3Q24 and into 4Q24; accelerating cost savings. B&S Group: 3Q24 preview - liquor bottoming into 4Q24? Coca-Cola Europacific Partners: Almost the real thing. D'Ieteren: Belgian October car registrations down 5.5%, VW down 11%. Kinepolis: Oct US/Canada box office at 59% of pre Covid level, France recovery to 78%. Recticel: 3Q24 compares well with Kingspan. Renewi: 1H25 preview - battling cost inflation with self help. Syensqo: Slight beat on 3Q...
We keep our HOLD rating but lower our target price from €1.20 to €1.10 reflecting our trimmed estimates. As long as we lack visibility on the outcome of the potential relaxation of the delivery model in mail and perhaps compensation for losses in the Universal Service Obligation (USO), we expect that inflationary pressures in Mail will balance out the upside potential in Parcels. This will in our view prevent a re-rating of the shares also as the soft economic outlook combined with intense compe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.